{"id":"NCT02526160","sponsor":"Kyowa Kirin, Inc.","briefTitle":"Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-22","primaryCompletion":"2016-12-22","completion":"2018-12-06","firstPosted":"2015-08-18","resultsPosted":"2021-02-05","lastUpdate":"2024-06-18"},"enrollment":134,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["X-linked Hypophosphatemia"],"interventions":[{"type":"BIOLOGICAL","name":"burosumab","otherNames":["UX023","KRN23","Crysvita"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Burosumab 1 mg/kg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary efficacy objective of this study is to establish the effect of burosumab treatment compared with placebo on increasing serum phosphorus levels in adults with XLH.","primaryOutcome":{"measure":"Percentage of Participants Achieving Mean Serum Phosphorus Levels Above the LLN (2.5 mg/dL [0.81 mmol/L]) at the Mid-Point of the Dose Interval, as Averaged Across Dose Cycles Between Baseline and Week 24","timeFrame":"Baseline through Week 24","effectByArm":[{"arm":"Placebo","deltaMin":7.6,"sd":null},{"arm":"Burosumab","deltaMin":92.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["United States","France","Ireland","Italy","Japan","South Korea","United Kingdom"]},"refs":{"pmids":["29947083","31165191","36854566","35927518","34548383"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":66},"commonTop":["Arthralgia","Nasopharyngitis","Headache","Back Pain","Fatigue"]}}